Mednet Logo
HomeHematology
Hematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

In what scenarios do you use a chromogenic factor X assay in adjusting INR goals for patients on warfarin?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Wisconsin

I do not use this method. It has been suggested that such assays be used in patients with lupus-type inhibitors who have significantly prolonged prothrombin times at baseline. In this setting, if the INR is "therapeutic," one would confirm an adequate warfarin effect if the factor X activity was in ...

What is a reasonable hemoglobin goal for patients with chronic anemia presenting with acute MI?

2
1 Answers

Mednet Member
Mednet Member
Cardiology · Mount Sinai Heart

The diversity of acute myocardial infarction (AMI) does not allow a monolithic answer to this question. The recent MINT study—an important contribution presented at AHA 2023 and published in NEJM—highlights this complexity. Although MINT, which randomized anemic patients with AMI to liberal versus r...

Would you continue or stop anticoagulation for a DVT/PE in a patient with active cancer who has completed 6 months of therapy?

1
3 Answers

Mednet Member
Mednet Member
General Internal Medicine · University of California, San Francisco

This is an important question that we didn’t really have a clear answer for… until this year when an NEJM RCT was published! Mahé et al., PMID 40162636 In this RCT, patients with cancer-associated VTE who completed 6 months of full-dose apixaban were randomized to half-dose apixaban vs. full-dos...

Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?

1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Brigham And Womens Hospital Respiratory Immunology Lab

Yes, MCAS may be diagnosed if a patient is on drugs known to cause non-specific mast cell activation.The reason for this answer requires a better understanding of MCAS criteria and etiology. In 2022, an expert consortium proposed revisions to the classification of mast cell activation disorders. (Va...

How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?

2
3 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · University of Rochester

As a pediatric hematologist/oncologist and pediatric palliative care physician, I can only speak to our approach with children, which may be quite different than the adult world. In our community, we are not able to provide blood or platelet transfusions in the home. For children who are profoundly ...

How do you approach patients who are inappropriately worried/fixated on a test result that is flagged as abnormal but not clinically significant?

3 Answers

Mednet Member
Mednet Member
Primary Care · Mount Sinai Doctors Medical Group

This happens all the time now. I tell them that those results were flagged as outside the reference range (I don't use the term abnormal) but that they are not clinically significant. It does not always work if there is a patient who is super anxious or hyper-focused. Typically, if they need a lot m...

Would you consider perioperative antifibrinolytics for mild factor 7 deficiency undergoing surgery?

1 Answers

Mednet Member
Mednet Member
Hematology · University of Pittsburgh Medical Center

I do use antifibrinolytics in factor VII deficiency; however, it depends on the specifics of the surgery (i.e., mucosal surface surgery, sequelae of bleeding should it occur - spine vs oral), the patient's bleeding history, and the factor VII level. Here, I wonder if the original diagnosis was corre...

Would you recommend anticoagulation prophylaxis for a pediatric patient admitted with COVID-19?

3 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · Case Western Reserve University School of Medicine

COVID-19 disease in children seems to be less severe than adults based on the current literature and our personal experience at Children's Hospitals. Among adults, the coagulopathy is beginning to be described with elevated inflammatory markers and other markers of coagulation activation, including ...

In which patients with atypical HUS would you consider eculizumab discontinuation?

1
2 Answers

Mednet Member
Mednet Member
Hematology · University of Minnestoa

My approach to eculizumab cessation in aHUS is to at least consider cessation in all patients not only given the high cost of the drug, but also given the risk of meningococcemia, which is incompletely protected against by vaccines.In treating aHUS, I initiate eculizumab (and preventive therapy for ...

Do you recommend GLP-1 agonists in patients with MPN?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · Massachusetts General Hospital

I agree with Dr. @Dr. First Last, although the data presented at SOHO were very provocative, demonstrating benefits to GLP-1 agonists in MPN patients, we do not currently have any prospective data or consensus guidelines to recommend the use of these agents for MPN alone. That being said, anecdotal...